VTE-BLEED Score
ورودیهای بالینی بیمار
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Low Risk0–1.9
- Elevated Risk2–10
The VTE-BLEED Score calculates assessing bleeding risk on anticoagulation therapy in patients with venous thromboembolism (VTE). Key inputs include age 60 or older. Scores guide initiating targeted anticoagulation therapy, platelet monitoring, or hematology specialist referral. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Assesses bleeding risk on anticoagulation therapy in patients with venous thromboembolism (VTE). This validated risk score enables better stratification of bleeding risk during stable anticoagulation after a first VTE episode. Unlike bleeding risk scores derived from atrial fibrillation patients, the VTE-BLEED score is specifically designed for VTE patients who have different comorbidity profiles and risk factors.
Clinical Indication
The VTE-BLEED Score is indicated for bedside clinical practice to support Assesses bleeding risk on anticoagulation therapy in patients with venous thromboembolism (VTE). This validated risk score enables better stratification of bleeding risk during stable anticoagulation after a first VTE episode. Unlike bleeding risk scores derived from atrial fibrillation patients, the VTE-BLEED score is specifically designed for VTE patients who have different comorbidity profiles and risk factors.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with coagulopathy, thrombocytopenia, venous thromboembolism (DVT/PE), or hematologic neoplasms. Clinical application is indicated across Hematology-oncology services, bone marrow transplant units, anticoagulation clinics, and acute medical wards.
Limitations & Contraindications
Severe thrombocytopenia with concomitant microvascular thrombosis (TTP, HIT, DIC) represents a medical emergency requiring rapid intervention. Clinical exclusion: Score should not be used as definitive exclusion from anticoagulation therapy.
Clinical Pearls & Action Plan
Detailed history of heparin exposure, platelet count kinetics, and comprehensive coagulation profiles are vital in consumptive coagulopathies. Guideline pearl: Designed for patients on stable anticoagulation after 30 days of treatment for DVT or PE.
Age ≥60 years (1.5 points) + Active cancer (2 points) + Male with uncontrolled hypertension (1 point) + Anemia (1.5 points) + History of bleeding (1.5 points) + Renal dysfunction (1.5 points). Score <2 = Low risk, Score ≥2 = Elevated risk.
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| age_60_or_older | string | Yes | Patient age 60 years or older |
| active_cancer | string | Yes | Active cancer (currently receiving treatment, treated within 6 months, or metastatic) |
| male_uncontrolled_hypertension | string | Yes | Male patient with uncontrolled hypertension (systolic BP >140 mmHg or diastolic BP >90 mmHg) |
| anemia | string | Yes | Anemia (hemoglobin <13 g/dL in men or <12 g/dL in women) |
| history_of_bleeding | string | Yes | History of bleeding (major bleeding episode requiring hospitalization, transfusion, or surgery) |
| renal_dysfunction | string | Yes | Renal dysfunction (creatinine clearance 30-60 mL/min) |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–1.9 | Low Risk | Low bleeding risk on anticoagulation |
| 2–10 | Elevated Risk | Elevated bleeding risk on anticoagulation |
Evidence-Based References (EBM)
- Klok FA, Hösel V, Clemens A, et al. Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment. Eur Respir J. 2016;48(5):1369-1376. doi: 10.1183/13993003.00280-2016DOI: 10.1183/13993003.00280-2016
- Barco S, Klok FA, Mahé I, et al. Impact of sex, age, and risk factors for venous thromboembolism on the risk of major bleeding in patients with acute venous thromboembolism. Circulation. 2020;141(1):8-17. doi: 10.1161/CIRCULATIONAHA.119.042716DOI: 10.1161/CIRCULATIONAHA.119.042716
- Mahé I, Chidiac J, Bertoletti L, et al. The clinical course of venous thromboembolism may differ according to cancer site. Am J Med. 2017;130(3):337-347. doi: 10.1016/j.amjmed.2016.10.017DOI: 10.1016/j.amjmed.2016.10.017
- Prandoni P, Noventa F, Ghirarduzzi A, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. Haematologica. 2007;92(2):199-205. doi: 10.3324/haematol.10516DOI: 10.3324/haematol.10516